Remote app monitoring for people with chronic heart failure
EVOLVING AZIMUTH IN MUSA CONTEXT
It will test whether using a smartphone telemonitoring app for people with chronic heart failure to report blood pressure and body weight helps support care and detect problems earlier.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 184 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Academic / other |
| Locations | 1 site (Milan, Italy) |
| Trial ID | NCT07022067 on ClinicalTrials.gov |
What this trial studies
Adults with chronic heart failure are randomized to an experimental arm that downloads and uses a telemonitoring app to enter blood pressure and weight data, or to a control arm without the app. The hospital clinical team reviews submitted data via a platform and both groups complete questionnaires at enrollment, three months, and six months. The trial focuses on non‑pharmacological impacts, explicitly measuring positive effects (co‑creation) and negative effects (co‑destruction) of the telemonitoring service. Outcomes combine patient‑reported measures and process metrics related to remote monitoring and care interaction.
Who should consider this trial
Good fit: Adults (18+) with chronic heart failure per ESC guidelines who have had recent hospital/ER access, can consent, own a compatible smartphone, and have home Wi‑Fi or mobile data are ideal candidates.
Not a fit: Patients with severe psychiatric disorders, inability or unwillingness to use portable technologies or the provided equipment, or those without a compatible smartphone or internet access are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the intervention could improve remote disease tracking, prompt earlier clinical responses, and help patients better self‑manage symptoms.
How similar studies have performed: Similar telemonitoring approaches for heart failure have produced mixed but promising results, with some trials reducing hospitalizations while others showed limited effect.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Have been diagnosed with chronic CS according to the ESC guidelines; * Over 18 years of age; * Patients admitted to hospital or with access to first aid within the last year; * Smartphome that meets the digital requirements (ie Android or iOS able to download and use the application); * Wi-Fi or 3G coverage at home; * Ability to give written informed consent. Exclusion Criteria: * Severe psychiatric disorder * Inability to use portable technologies * Patients unable to use the equipment provided * Patients who deny consent to study participation
Where this trial is running
Milan, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Italy, Italy (Recruiting)
Study contacts
- Principal investigator: Stefano Prof. Carugo — IRCCS Fondazione Caì Granda Ospedale Maggiore Policlinico
- Study coordinator: Stefano Prof. Carugo
- Email: stefano.carugo@policlinico.mi.it
- Phone: +390255033532
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.